Press Releases – SynAct Pharma

May 8, 2025

Non Regulatory

SynAct to host Capital Markets Day in Stockholm June 4

April 23, 2025

Non Regulatory

SynAct receives Notice of Allowance for grant of US Patent covering resomelagon (AP1189) combination therapy

April 16, 2025

Non Regulatory

SynAct Pharma to participate at BIO International Convention in Boston June 16-19

April 11, 2025

Non Regulatory

SynAct Pharma Announces Initiation of Phase II Study with resomelagon (AP1189) for the Treatment of Patients with Dengue

March 17, 2025

Non Regulatory

The European Patent Office issues an Intention to Grant a European Patent Covering the Clinical Formulation of Resomelagon (AP1189)

March 4, 2025

Non Regulatory

Pivotal US Patent Protecting Resomelagon (AP1189) Granted to SynAct Pharma